GLP1R and metabolic dysfunction-associated steatotic liver disease: Our study paves the way for future in vivo studies to better understand the contribution of the modulation of the miRNA profile of hepatocytes, and maybe other liver cells, to the positive effect of GLP-1R agonists on NAFLD.